Risk Factors of Paraspinal Muscles in Degenerative Lumbar Spondylolisthesis (RFPMDLS)
Prediction of Risk Factors of Paraspinal Muscles in Degenerative Lumbar Spondylolisthesis Based on Spine MRI
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Xinyun Li
- Phone Number: 86+15750359757
- Email: 15750359757@163.com
Study Locations
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- The First People's Hospital of Yunnan
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who presented to our hospital with back pain(the diagnosis was spondylolisthesis or no spondylolisthesis);
- Patients older than 50 years;
- Patients with complete clinical data and magnetic resonance imaging (MRI) before surgery.
Exclusion Criteria:
- The patient has previous spinal surgery;
- Patients with lumbar tumor,lumbar infection and lumbar tuberculosis;
- Patients with incomplete MRI sequence.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Group A
patients without lumbar spondylolisthesis
|
|
Group B
patients with lumbar spondylolisthesis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the MF FCSA
Time Frame: Two weeks before treatment
|
The functional cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
|
Two weeks before treatment
|
|
the ES FCSA
Time Frame: Two weeks before treatment
|
The functional cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
|
Two weeks before treatment
|
|
the MF CSA
Time Frame: Two weeks before treatment
|
the total cross-sectional areas of the multifidus muscl.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
|
Two weeks before treatment
|
|
the ES CSA
Time Frame: Two weeks before treatment
|
the total cross-sectional areas of the erector spinae.Measurement it on axial T2-weighted magnetic resonance (MR) images from the L4 vertebral body levels
|
Two weeks before treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SMI
Time Frame: Two weeks before treatment
|
The skeletal muscle index.SMI = l CSA of muscle on an axial scan (expressed as cm2) divided by the square of the patient's height (expressed as cm2).
|
Two weeks before treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- KHLL2025-KY047
- 2024JSKFKT-17 (Other Grant/Funding Number: Yunnan Spinal Cord Disease Clinical Medical Center)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.